GRM 2010 GRM 2011

Abstract Details

Family Name:
First Name:
Title of Paper:
Recent Developments in Brazil, India China and UAE Intellectual Property Laws and investment policies in WTO regime: A comparative analysis of the efficiency to attract foreign investment and biopharma innovation
Paper Proposal Text :

In many countries around the world, certain problems are involved in implementing TRIPS-mandated standards into domestic law, and in enforcing existing domestic patent laws. In addition, Brazil, China UAE and India have established themselves as leaders of a coalition of developing nations.
Brazil, China, UAE and India are all fast-growing economies with large markets and populations, and they have been of particular concern for research-based biopharmaceutical companies. These three countries also have substantial generic drug industries which are often able to exert a significant influence on commercial and IP policies and now transitioning from generic innovation to novel drugs innovation and for the same they need international collaborations.
This chapter compares how differences in the Intellectual Property laws, their enforcement regimes along with other related investment laws of India, Brazil UAE and China impact the choice of location and investment decisions of multinational corporations (MNCs) and biopharma firms.
The paper attempts to make comparisons between the patent laws, drugs regulations and other investment laws of India, Brazil, UAE and China on the basis of legal text, landmark court cases and on the basis of personal interviews with CEOs of biopharma companies who have made investments in these countries.
This paper examines the outcomes of technology transfer policies adopted in the past 20 years by five middle-income countries: Brazil, India, UAE and China. This paper looks at how technology transfer policies have affected countries from three different regions (the Middle East, Asia, and latin America) in the past 20 years. This is done in order to know the impact of TRIPs agreement of WTO on the biopharmaceutical industry of developing countries.
The central issue in this study is the extent to which patent reform (after the imposition of the TRIPs agreement) and investment policy reforms have affected these countries ability to attract technology transfer for the biopharmaceutical drugs innovation.
The result suggest that countries with the balance of good investment climate, good governance and better policies with market strengths have greater in technology transfer and innovation. Without this balance, technology transfer will have limited effects and innovation also gets impacted.
Key Words: Biopharma, Investment policies, WTP, Patent, India, China, Brazil, UAE